We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Regenerative Medicine at Organogenesis

Regenerative Medicine at Organogenesis

The field of Regenerative Medicine is developing and coming into its own. As a pioneer in this field, Organogenesis is proud to have been at the forefront of this new era since its early days as an MIT-spin-off, all the way through making this technology into a reality for patients today.

A new era in medicine arrived when Organogenesis received one of the first FDA approvals for a living, human cell-based product. Apligraf® and Dermagraft® are now the leading regenerative medicine brands in the world.

The development of Organogenesis’ first technology platform (delivering living cells to the body via a 3-D construct) was one of the field's first major breakthroughs.